ADORA2A and neoplasm: The mechanism is based on the increase in cAMP after the activation of Gs-coupled A2ARs. Consequently, a selective A2AR antagonist releases this brake and reduces cAMP levels which, in turn, make lymphocytes capable of effectively fighting/destroying tumor cells (Figure 1B).